These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19532079)

  • 21. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay.
    Labrecque J; Metz M; Lau G; Darkes MC; Wong RS; Bogucki D; Carpenter B; Chen G; Li T; Nan S; Schols D; Bridger GJ; Fricker SP; Skerlj RT
    Virology; 2011 May; 413(2):231-43. PubMed ID: 21388649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotyping methods for determining HIV tropism and applications in clinical settings.
    Raymond S; Delobel P; Izopet J
    Curr Opin HIV AIDS; 2012 Sep; 7(5):463-9. PubMed ID: 22832712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New kinds of AIDS drugs inhibit HIV entry into the cell. Entry inhibitors soon for oral administration].
    Fätkenheuer G
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():46-8. PubMed ID: 16385874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Entry inhibitors and their use in the treatment of HIV-1 infection.
    Haqqani AA; Tilton JC
    Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances of CCR5 antagonists.
    Baba M
    Curr Opin HIV AIDS; 2006 Sep; 1(5):367-72. PubMed ID: 19372835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac.
    Chen Z; Gettie A; Ho DD; Marx PA
    Virology; 1998 Jun; 246(1):113-24. PubMed ID: 9656999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 entry inhibitors: recent development and clinical use.
    Henrich TJ; Kuritzkes DR
    Curr Opin Virol; 2013 Feb; 3(1):51-7. PubMed ID: 23290628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.
    Klibanov OM
    Curr Opin Investig Drugs; 2009 Aug; 10(8):845-59. PubMed ID: 19649929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.
    Smith EB; Ogert RA; Pechter D; Villafania A; Abbondanzo SJ; Lin K; Rivera-Gines A; Rebsch-Mastykarz C; Monsma FJ
    J Biomol Screen; 2014 Jan; 19(1):108-18. PubMed ID: 23989454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [CCR5 antagonists: a new class of antiretrovirals].
    Peytavin G; Calvez V; Katlama C
    Therapie; 2009; 64(1):9-16. PubMed ID: 19463248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Entry inhibitors: a race to the finish line.
    Proj Inf Perspect; 2006 Jan; (40):7-12. PubMed ID: 16718905
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors.
    Chen W; Zhan P; De Clercq E; Liu X
    Curr Pharm Des; 2012; 18(1):100-12. PubMed ID: 22236118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The HIV entry inhibitors revisited.
    Leonard JT; Roy K
    Curr Med Chem; 2006; 13(8):911-34. PubMed ID: 16611075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upcoming drugs that inhibit viral entry will be a new frontier for antiretroviral therapy.
    Murphy MJ
    HIV Clin; 2002; 14(4):1-3. PubMed ID: 12434756
    [No Abstract]   [Full Text] [Related]  

  • 35. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
    Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
    Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [CCR5 antagonists: a new class of antiretrovirals].
    de la Tribonnière X; Yazdanpanah Y; Reynes J
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S1-6. PubMed ID: 18455055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemokine antagonists as therapeutics: focus on HIV-1.
    Tsibris AM; Kuritzkes DR
    Annu Rev Med; 2007; 58():445-59. PubMed ID: 16958560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of CXCR4 in HIV infection and its potential as a therapeutic target.
    Murakami T; Yamamoto N
    Future Microbiol; 2010 Jul; 5(7):1025-39. PubMed ID: 20632803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.
    Westby M; van der Ryst E
    Antivir Chem Chemother; 2005; 16(6):339-54. PubMed ID: 16329283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement.
    Markovic I
    Curr Pharm Des; 2006; 12(9):1105-19. PubMed ID: 16515489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.